MHRA Updates Pharmacovigilance Procedures for UK Authorised Products

• The MHRA has updated its guidance on pharmacovigilance procedures for UK authorised products.
• Changes include revised submission requirements for signals, RMPs, PASS, and PSURs.
• New sections on MHRA Safety Reviews and Safety Communications have been added to the guidance.

The changes aim to enhance transparency and efficiency in pharmacovigilance processes, ensuring that UK authorised products comply with EU good pharmacovigilance practices.

The MHRA has updated its guidance on pharmacovigilance procedures for UK authorised products, incorporating changes to submission requirements for signals, Risk Management Plans (RMPs), Post Authorisation Safety Studies (PASS), and Periodic Safety Update Reports (PSURs). The revised guidance also includes new sections on MHRA Safety Reviews and Safety Communications. Furthermore, the updated pharmacovigilance procedures now provide clarity on submission and documentation requirements for various pharmacovigilance procedures, including reliance procedures.

The changes aim to enhance transparency and efficiency in pharmacovigilance processes, ensuring that UK authorised products comply with EU good pharmacovigilance practices. The MHRA's updated guidance is a critical resource for lawyers advising pharmaceutical companies on compliance with pharmacovigilance requirements.

The updated guidance reflects the impact of the Windsor Framework on pharmacovigilance in the UK, as well as the exceptions and modifications to EU good pharmacovigilance practices that apply to UK MAHs. The MHRA's pharmacovigilance requirements for UK authorised products are now aligned with these changes, ensuring a seamless transition post-Brexit. Additionally, the guidance acknowledges the importance of Periodic Safety Update Reports (PSURs) in maintaining public health and safety.

The updated pharmacovigilance procedures also incorporate new video entries and webinar recordings, providing further clarity on submission requirements for various pharmacovigilance procedures. The MHRA's commitment to transparency and collaboration is evident in its provision of resources, including the pharmacovigilance Windsor Framework guidance and Q&A document.

The updated MHRA guidance on pharmacovigilance procedures has significant implications for lawyers advising pharmaceutical companies. The revised submission requirements for signals, RMPs, PASS, and PSURs necessitate a thorough review of existing practices to ensure compliance with the new guidelines. Furthermore, the inclusion of new sections on MHRA Safety Reviews and Safety Communications underscores the importance of effective communication in pharmacovigilance.

The updated guidance also highlights the need for pharmaceutical companies to adapt to changing regulatory requirements, particularly in light of the Windsor Framework's impact on pharmacovigilance in the UK. By staying informed about these developments, lawyers can provide expert advice and support to their clients, ensuring continued compliance with pharmacovigilance regulations.

Lawyers advising pharmaceutical companies should review the updated MHRA guidance on pharmacovigilance procedures, particularly with regards to submission requirements for signals, Risk Management Plans (RMPs), Post Authorisation Safety Studies (PASS), and Periodic Safety Update Reports (PSURs).

Source: Original reporting via GOV.UK